Pyridinium, 4-(2-(((6R,7R)-2-carboxy-7-(((2Z)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)thio)-4-thiazolyl)-1-methyl-, inner salt

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ceftaroline fosamil

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

J01DI02

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

The time that unbound plasma concentration of ceftaroline exceeds the minimum inhibitory concentration (MIC) of the infecting organism has been shown to best correlate with efficacy in a neutropenic murine thigh infection model with S. aureus and S. pneumoniae. No significant effect on QTc (corrected QT interval) interval was detected at peak plasma concentration or at any other time.

CEFTAROLINE FOSAMIL

Cephalosporins [CS]; Cephalosporin Antibacterial [EPC]

primarily eliminated by the kidneys (6% in feces within 48 hours).

Median 20.3 L (18.3-21.6 L).